Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis

Objective: Cardiac amyloidosis (CA) is associated with a poor prognosis and a survival rate of less than 30% 2 years after clinical manifestation. Considered as a semi-malignant disease, CA is often a contraindication for HTx; however, depending on the type of CA, there are excellent treatment regim...

Full description

Saved in:
Bibliographic Details
Main Authors: Sack, Falk-Udo (Author) , Kristen, Arnt (Author) , Goldschmidt, Hartmut (Author) , Schnabel, Philipp Albert (Author) , Dengler, Thomas (Author) , Koch, Achim (Author) , Karck, Matthias (Author)
Format: Article (Journal)
Language:English
Published: 01 February 2008
In: European journal of cardio-thoracic surgery
Year: 2008, Volume: 33, Issue: 2, Pages: 257-262
ISSN:1873-734X
DOI:10.1016/j.ejcts.2007.10.025
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejcts.2007.10.025
Get full text
Author Notes:Falk-Udo Sack, Arnt Kristen, Hartmut Goldschmidt, Philipp A. Schnabel, Thomas Dengler, Achim Koch, Matthias Karck

MARC

LEADER 00000caa a2200000 c 4500
001 1786890658
003 DE-627
005 20230428185127.0
007 cr uuu---uuuuu
008 220121s2008 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ejcts.2007.10.025  |2 doi 
035 |a (DE-627)1786890658 
035 |a (DE-599)KXP1786890658 
035 |a (OCoLC)1341438950 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sack, Falk-Udo  |e VerfasserIn  |0 (DE-588)1075076951  |0 (DE-627)832921114  |0 (DE-576)443246440  |4 aut 
245 1 0 |a Treatment options for severe cardiac amyloidosis  |b heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis  |c Falk-Udo Sack, Arnt Kristen, Hartmut Goldschmidt, Philipp A. Schnabel, Thomas Dengler, Achim Koch, Matthias Karck 
264 1 |c 01 February 2008 
300 |b Illustrationen 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 21 December 2007 
500 |a Gesehen am 21.01.2022 
520 |a Objective: Cardiac amyloidosis (CA) is associated with a poor prognosis and a survival rate of less than 30% 2 years after clinical manifestation. Considered as a semi-malignant disease, CA is often a contraindication for HTx; however, depending on the type of CA, there are excellent treatment regimes that can be combined with HTx. In AL-amyloidosis, chemotherapy and stem cell transplantation are necessary and in TTR-amyloidosis, where the liver is the source of the pathologic protein, liver transplantation is recommended after HTx. Methods and Results: More than 60 patients with AL-amyloidosis and more than 25 patients with ATTR-amyloidosis have been investigated at our centre. Eighteen patients showed signs of end-stage heart failure. Four patients died within 1 month after listing for HTx. Seven patients with AL (mean age 41.8 years) and five patients with ATTR-amyloidosis (mean age 42.6 years) were successfully transplanted with an actual survival rate of 91.6%. One patient died 8 months after HTx due to infection. Five AL patients received chemotherapy and SCT and one ATTR patient was liver transplanted. Three AL patients showed complete remission of amyloidosis. Conclusions: Cardiac amyloidosis is a potentially curative disease after HTx when combined with either chemotherapy and SCT or LiverTx depending on the type of the amyloidosis. Due to the natural course of the disease, urgent HTx after cardiac manifestation is mandatory. With this approach, excellent survival rates and even remission of the underlying disease is possible. 
700 1 |a Kristen, Arnt  |d 1974-  |e VerfasserIn  |0 (DE-588)123480965  |0 (DE-627)706314530  |0 (DE-576)293726876  |4 aut 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
700 1 |a Schnabel, Philipp Albert  |d 1953-2021  |e VerfasserIn  |0 (DE-588)102254960X  |0 (DE-627)717000087  |0 (DE-576)16982750X  |4 aut 
700 1 |a Dengler, Thomas  |e VerfasserIn  |0 (DE-588)1077763050  |0 (DE-627)837469198  |0 (DE-576)184645417  |4 aut 
700 1 |a Koch, Achim  |d 1969-  |e VerfasserIn  |0 (DE-588)124512801  |0 (DE-627)575606118  |0 (DE-576)294207864  |4 aut 
700 1 |a Karck, Matthias  |d 1961-  |e VerfasserIn  |0 (DE-588)130833525  |0 (DE-627)505909340  |0 (DE-576)298366169  |4 aut 
773 0 8 |i Enthalten in  |t European journal of cardio-thoracic surgery  |d Oxford : Oxford Univ. Press, 1987  |g 33(2008), 2, Seite 257-262  |h Online-Ressource  |w (DE-627)306658275  |w (DE-600)1500330-9  |w (DE-576)081985975  |x 1873-734X  |7 nnas  |a Treatment options for severe cardiac amyloidosis heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis 
773 1 8 |g volume:33  |g year:2008  |g number:2  |g pages:257-262  |g extent:6  |a Treatment options for severe cardiac amyloidosis heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis 
856 4 0 |u https://doi.org/10.1016/j.ejcts.2007.10.025  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220121 
993 |a Article 
994 |a 2008 
998 |g 130833525  |a Karck, Matthias  |m 130833525:Karck, Matthias  |d 910000  |d 910200  |e 910000PK130833525  |e 910200PK130833525  |k 0/910000/  |k 1/910000/910200/  |p 7  |y j 
998 |g 124512801  |a Koch, Achim  |m 124512801:Koch, Achim  |d 910000  |d 910200  |e 910000PK124512801  |e 910200PK124512801  |k 0/910000/  |k 1/910000/910200/  |p 6 
998 |g 1077763050  |a Dengler, Thomas  |m 1077763050:Dengler, Thomas  |d 910000  |d 910100  |e 910000PD1077763050  |e 910100PD1077763050  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 102254960X  |a Schnabel, Philipp Albert  |m 102254960X:Schnabel, Philipp Albert  |d 910000  |d 912000  |e 910000PS102254960X  |e 912000PS102254960X  |k 0/910000/  |k 1/910000/912000/  |p 4 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |d 50000  |e 910000PG102258023X  |e 910100PG102258023X  |e 50000PG102258023X  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 3 
998 |g 123480965  |a Kristen, Arnt  |m 123480965:Kristen, Arnt  |d 910000  |d 910100  |e 910000PK123480965  |e 910100PK123480965  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1075076951  |a Sack, Falk-Udo  |m 1075076951:Sack, Falk-Udo  |d 910000  |d 910200  |e 910000PS1075076951  |e 910200PS1075076951  |k 0/910000/  |k 1/910000/910200/  |p 1  |x j 
999 |a KXP-PPN1786890658  |e 4040842154 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.1016/j.ejcts.2007.10.025"],"eki":["1786890658"]},"name":{"displayForm":["Falk-Udo Sack, Arnt Kristen, Hartmut Goldschmidt, Philipp A. Schnabel, Thomas Dengler, Achim Koch, Matthias Karck"]},"physDesc":[{"noteIll":"Illustrationen","extent":"6 S."}],"recId":"1786890658","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Available online 21 December 2007","Gesehen am 21.01.2022"],"title":[{"subtitle":"heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis","title":"Treatment options for severe cardiac amyloidosis","title_sort":"Treatment options for severe cardiac amyloidosis"}],"origin":[{"dateIssuedKey":"2008","dateIssuedDisp":"01 February 2008"}],"person":[{"family":"Sack","given":"Falk-Udo","role":"aut","display":"Sack, Falk-Udo"},{"role":"aut","given":"Arnt","family":"Kristen","display":"Kristen, Arnt"},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","given":"Hartmut","role":"aut"},{"display":"Schnabel, Philipp Albert","given":"Philipp Albert","role":"aut","family":"Schnabel"},{"display":"Dengler, Thomas","family":"Dengler","role":"aut","given":"Thomas"},{"role":"aut","given":"Achim","family":"Koch","display":"Koch, Achim"},{"family":"Karck","given":"Matthias","role":"aut","display":"Karck, Matthias"}],"relHost":[{"title":[{"subtitle":"official journal of the European Association for Cardio-Thoracic Surgery and the European Society of Thoracic Surgeons","title_sort":"European journal of cardio-thoracic surgery","title":"European journal of cardio-thoracic surgery"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 15.01.2021"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"origin":[{"dateIssuedKey":"1987","dateIssuedDisp":"1987-","publisherPlace":"Oxford ; Amsterdam [u.a.]","publisher":"Oxford Univ. Press ; Elsevier Science"}],"disp":"Treatment options for severe cardiac amyloidosis heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosisEuropean journal of cardio-thoracic surgery","recId":"306658275","physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"2","text":"33(2008), 2, Seite 257-262","extent":"6","pages":"257-262","volume":"33","year":"2008"},"id":{"zdb":["1500330-9"],"issn":["1873-734X"],"eki":["306658275"]},"titleAlt":[{"title":"Cardio-thoracic surgery"}],"pubHistory":["1.1987 -"]}]} 
SRT |a SACKFALKUDTREATMENTO0120